MTOR and nonpapillary renal cell carcinoma: Specifically, the development of targeted therapeutics, including immune checkpoint, multi-targeted tyrosine kinase, and mTOR inhibitors, revolutionized the treatment of patients with clear cell renal cell carcinoma (ccRCC) [1,2].